Study Results Show Sustained Improvement, Minimal Adverse Effects

Results of two Phase 3 studies reported promising results for naloxegol, a new investigational once-daily drug for the treatment of opioid induced constipation. The results appear online in the New England Journal of Medicine.

Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist specifically designed for the treatment of opioid-induced constipation (OIC). The studies showed that a 25 mg daily dose safely increased bowel movements among opioid-induced constipation sufferers, compared to a placebo, and that the improvement was sustained over a 12-week treatment period. Read a news story about the study here.


Related Content